Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors
Serina Therapeutics (NYSE: SER) has appointed Dr. Stephen Brannan to its Board of Directors. Dr. Brannan brings over 30 years of experience in neuroscience and neuropsychiatry drug development. He most recently served as Chief Medical Officer at Karuna Therapeutics, where he led the clinical development of KarXT, the first new schizophrenia treatment mechanism in over 30 years, which contributed to Karuna's $14 billion acquisition by Bristol Myers Squibb in 2024.
Dr. Brannan's extensive experience includes senior leadership roles at Takeda, Novartis, Cyberonics, and Eli Lilly, where he directed clinical programs in various CNS conditions. He will support Serina's strategic development of long-acting CNS therapeutics using their proprietary POZ Platform™ technology. The company also announced the departure of Remy Gross from its Board, who will continue supporting the team in a consulting role.
Serina Therapeutics (NYSE: SER) ha nominato Dr. Stephen Brannan nel suo Consiglio di Amministrazione. Il Dr. Brannan vanta oltre 30 anni di esperienza nello sviluppo di farmaci per neuroscienze e neuropsichiatria. Recentemente è stato Chief Medical Officer presso Karuna Therapeutics, dove ha guidato lo sviluppo clinico di KarXT, il primo nuovo meccanismo di trattamento per la schizofrenia in oltre 30 anni, contribuendo all'acquisizione di Karuna da 14 miliardi di dollari da parte di Bristol Myers Squibb nel 2024.
L'ampia esperienza del Dr. Brannan include ruoli di leadership senior presso Takeda, Novartis, Cyberonics ed Eli Lilly, dove ha diretto programmi clinici per diverse patologie del sistema nervoso centrale. Supporterà lo sviluppo strategico di Serina di terapie CNS a lunga durata d'azione utilizzando la loro tecnologia proprietaria POZ Platform™. L'azienda ha inoltre annunciato l'uscita di Remy Gross dal Consiglio, che continuerà a supportare il team in qualità di consulente.
Serina Therapeutics (NYSE: SER) ha nombrado a Dr. Stephen Brannan en su Junta Directiva. El Dr. Brannan aporta más de 30 años de experiencia en el desarrollo de fármacos para neurociencia y neuropsiquiatría. Recientemente se desempeñó como Director Médico en Karuna Therapeutics, donde lideró el desarrollo clínico de KarXT, el primer nuevo mecanismo de tratamiento para la esquizofrenia en más de 30 años, lo que contribuyó a la adquisición de Karuna por 14 mil millones de dólares por Bristol Myers Squibb en 2024.
La amplia experiencia del Dr. Brannan incluye cargos de liderazgo senior en Takeda, Novartis, Cyberonics y Eli Lilly, donde dirigió programas clínicos en diversas condiciones del sistema nervioso central. Apoyará el desarrollo estratégico de Serina de terapias CNS de acción prolongada utilizando su tecnología propietaria POZ Platform™. La compañía también anunció la salida de Remy Gross de su Junta, quien continuará apoyando al equipo como consultor.
Serina Therapeutics (NYSE: SER)는 Dr. Stephen Brannan을 이사회에 임명했습니다. Brannan 박사는 신경과학 및 신경정신약 개발 분야에서 30년 이상의 경험을 보유하고 있습니다. 그는 최근 Karuna Therapeutics의 최고 의료 책임자로 재직하며, 30년 만에 처음으로 새로운 조현병 치료 메커니즘인 KarXT의 임상 개발을 이끌었으며, 이는 2024년 Bristol Myers Squibb가 Karuna를 140억 달러에 인수하는 데 기여했습니다.
Brannan 박사의 폭넓은 경험에는 Takeda, Novartis, Cyberonics, Eli Lilly에서의 고위 리더십 역할이 포함되며, 다양한 중추신경계 질환의 임상 프로그램을 지휘했습니다. 그는 Serina의 독자적 POZ Platform™ 기술을 활용한 장기 작용 CNS 치료제의 전략적 개발을 지원할 예정입니다. 회사는 또한 이사회에서 Remy Gross의 퇴임을 발표했으며, 그는 컨설턴트 역할로 팀을 계속 지원할 것입니다.
Serina Therapeutics (NYSE : SER) a nommé Dr Stephen Brannan à son conseil d'administration. Le Dr Brannan apporte plus de 30 ans d'expérience dans le développement de médicaments en neurosciences et neuropsychiatrie. Il a récemment occupé le poste de directeur médical chez Karuna Therapeutics, où il a dirigé le développement clinique de KarXT, le premier nouveau mécanisme de traitement de la schizophrénie depuis plus de 30 ans, ce qui a contribué à l'acquisition de Karuna par Bristol Myers Squibb pour 14 milliards de dollars en 2024.
L'expérience étendue du Dr Brannan inclut des postes de direction chez Takeda, Novartis, Cyberonics et Eli Lilly, où il a supervisé des programmes cliniques pour diverses affections du système nerveux central. Il soutiendra le développement stratégique de Serina de thérapies CNS à action prolongée utilisant leur technologie propriétaire POZ Platform™. La société a également annoncé le départ de Remy Gross du conseil, qui continuera à soutenir l'équipe en tant que consultant.
Serina Therapeutics (NYSE: SER) hat Dr. Stephen Brannan in seinen Vorstand berufen. Dr. Brannan bringt über 30 Jahre Erfahrung in der Entwicklung von Medikamenten für Neurowissenschaften und Neuropsychiatrie mit. Zuletzt war er Chief Medical Officer bei Karuna Therapeutics, wo er die klinische Entwicklung von KarXT leitete, dem ersten neuen Behandlungsmechanismus für Schizophrenie seit über 30 Jahren, was zum 14-Milliarden-Dollar-Erwerb von Karuna durch Bristol Myers Squibb im Jahr 2024 beitrug.
Dr. Brannans umfangreiche Erfahrung umfasst leitende Positionen bei Takeda, Novartis, Cyberonics und Eli Lilly, wo er klinische Programme für verschiedene ZNS-Erkrankungen leitete. Er wird Serinas strategische Entwicklung von langwirksamen CNS-Therapeutika mit der firmeneigenen POZ Platform™ Technologie unterstützen. Das Unternehmen gab außerdem den Austritt von Remy Gross aus dem Vorstand bekannt, der das Team weiterhin in beratender Funktion unterstützt.
- Addition of highly experienced neuroscience expert Dr. Brannan, who led the successful development of KarXT at Karuna Therapeutics
- Dr. Brannan's track record includes contributing to Karuna's $14B acquisition by Bristol Myers Squibb
- Strategic expertise in CNS drug development from leadership roles at major pharmaceutical companies
- None.
- Renowned neuroscience drug developer joins to support strategic development
of long-acting CNS therapeutics –
HUNTSVILLE, AL, May 22, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing a pipeline of product candidates leveraging its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Stephen (Steve) Brannan, M.D., to its Board of Directors.
Dr. Brannan brings more than three decades of experience in neuroscience and neuropsychiatry drug development, with a proven track record of leading clinical programs from early development through regulatory approval and commercialization. Most recently, he served as Chief Medical Officer at Karuna Therapeutics, where he led the clinical strategy for KarXT (xanomeline–trospium), the first new mechanism of action for schizophrenia approved in over 30 years. KarXT’s successful development and launch were key to Karuna’s
“Steve brings a rare depth of clinical and strategic expertise in neuroscience drug development, and we’re pleased to welcome him to the Board,” said Steve Ledger, Chief Executive Officer of Serina Therapeutics. “At Karuna, he helped shape the clinical path for KarXT, a first-in-class therapy that ultimately drove one of the largest CNS acquisitions in recent years. His experience designing thoughtful, data-driven trials and his understanding of patient and commercial needs are highly aligned with Serina’s focus on long-acting treatments for movement disorders and other CNS conditions. We look forward to his contributions as we advance our pipeline toward the clinic.”
Dr. Brannan previously held senior leadership roles at Takeda, Novartis, Cyberonics (now LivaNova), and Eli Lilly, where he directed clinical development programs in depression, Alzheimer’s disease, schizophrenia, and treatment-resistant epilepsy. At Takeda, he led turnaround efforts that rescued and advanced multiple late-stage CNS programs. He is a founding member of the CNS Summit Leadership Council and has served on the Executive Committee of the International Society for CNS Clinical Trials and Methodology (ISCTM), reflecting his continued influence on the field’s evolving standards and methodologies.
Dr. Brannan received his A.B. from Harvard University and his M.D. from the University of Texas Southwestern Medical School. He completed residency and fellowship training in psychiatry and neuroimaging, and has served in academic, clinical, and industry leadership roles throughout his career.
Serina also announced the departure of Remy Gross from its Board of Directors. Mr. Ledger stated, “Remy has been a trusted advisor to the team at Serina for many years. We thank Remy for his contributions to Serina’s growth from private to public company and his continuing support of the team in a new consulting role. "
About Serina Therapeutics
Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ Platform™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.
For more information, please visit https://serinatherapeutics.com.
For inquiries, please contact:
Stefan Riley
sriley@serinatherapeutics.com
(256) 327-9630
FAQ
Who is Dr. Stephen Brannan and why did Serina Therapeutics (SER) appoint him to their Board?
What experience does Dr. Brannan bring to Serina Therapeutics' (SER) Board?
What is Serina Therapeutics' (SER) main focus and technology?
What changes occurred in Serina Therapeutics' (SER) Board of Directors in May 2025?
